{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-110374","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.995430+00:00","generated_at":"2026-05-17T11:10:29.138798+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tivic Health receives two INDs for Entolimod from Statera for ARS and advanced cancers","bullets":["Completed transfer of two INDs from Statera Biopharma for lead candidate Entolimod.","INDs cover acute radiation syndrome (ARS-H and ARS-GI sub-syndromes) and advanced cancers.","Enables formal FDA engagement on regulatory pathway for ARS; near-term focus on ARS as first indication.","Also enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-treatment conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-110374","json":"https://secwatch.observer/filing/0000950170-25-110374.json","markdown":"https://secwatch.observer/filing/0000950170-25-110374.md","text":"https://secwatch.observer/filing/0000950170-25-110374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025110374/0000950170-25-110374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025110374/tivc-20250820.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:10:29.138798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}